Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 13CNS 7Head & Neck 4Gastrointestinal 4Sarcoma 3Gynecologic 2Genitourinary 2Thoracic 1Dermatologic 1

Conditions

Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lapatinib × Genitourinary × Clear all
NCT00103194 2014-09-30

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
49 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00095667 2013-05-08

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡